Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad s Q1 Revenues Grow 3 Percent As Net Income Declines 7 Percent

NEW YORK, May 5 (GenomeWeb News) – Bio-Rad reported yesterday a 3 percent increase in its first-quarter revenues to $308.3 million from $299.2 million during the year-ago period. Net income decreased 6.9 percent to $31.2 million from $33.5 million during the first quarter of 2005. Research and development grew 4.7 percent to $28.1 million from $26.8 million a year ago. Net sales from Bio-Rad’s Life Science segment were $144.8 million, up 0.5 percent from $144.1 million during the first quarter of 2005. The Clinical Diagnostics segment reported net sales of $160.3 million for the quarter, up 5.5 percent compared to the prior-year quarter. As of March 31, Bio-Rad had $265.6 million in cash and cash equivalents.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.